The Effect of Semaglutide in Non-Cirrhotic Non-Alcoholic Steatohepatitis

Brief description of study

We are doing this study to see if the medicine called semaglutide can help patients with NASH get better and reduce their risk of future liver complications. NASH is a disease where fat, inflammation and scar tissue build up in the liver. Semaglutide may improve these liver damages. By improving liver damage it might be possible to prevent future liver complications.

Semaglutide is already used by doctors to treat patients with type 2 diabetes in many countries. It is also used in research studies of patients with obesity and of patients with different stages of NASH. However, its use for your condition is not approved by the US Food and Drug administration. Its use in this study is therefore considered experimental.

This study will mainly look at changes in your liver after treatment with semaglutide. The study will also look at complications related to your liver disease. This is done by:

  • Comparing liver tissue samples taken at the study start with liver tissue samples taken later in the study.
  • Collecting information about any liver complications you may have while being in the study.


Clinical Study Identifier: s20-01271
ClinicalTrials.gov Identifier: NCT04822181
Principal Investigator: Ira M. Jacobson.
Other Investigators: Monique Julia Carasso, Ilyse Haberman, Mary Christine Olson.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.